3rd Annual GLP-1 Based Therapeutics Summit

Welcome to the 3rd GLP-1 Based Therapeutics Summit – the essential industry forum dedicated to solving the critical challenges of GLP-1 combinations, mastering tolerability, drug delivery, and seizing the multi-billion dollar opportunity in non-obesity indications.

Driven by unprecedented clinical success, this revolutionary drug class has created multi-billion dollar franchises, but the market is now reaching a critical juncture where differentiation is everything. The pressure is on to move beyond monotherapy and unlock new levels of efficacy in areas like neuroscience and cardiorenal protection, promising unparalleled potential to conquer widespread chronic diseases.

The 3rd GLP-1 Based Therapeutics Summit stands as the global forum for experts dedicated to accelerating this vital progress. This year, we’re diving deep into the game-changing potential of multi-agonist combinations, next-generation tolerability, and strategic commercial planning.

Hear from the titans of the pharmaceutical industry, including Eli Lilly, AstraZeneca, Merck, and Takeda, as well as innovative biotechs and financial institutions who will share their groundbreaking research and strategies for developing best-in-class treatments that transform patient lives.

View the full event guide: https://ter.li/p453jn